"7"^^ . "http://www.prolekare.cz/linkout/48816" . . "Dvo\u0159\u00E1k, Josef" . . "Combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma"@en . . "CZ - \u010Cesk\u00E1 republika" . "11110" . "RIV/00216208:11110/14:10283162" . "epidermal growth factor receptor; monoclonal antibodies; chemoradiotherapy; rectal cancer"@en . . . "Karcinom rekta se li\u0161\u00ED od karcinomu tlust\u00E9ho st\u0159eva vy\u0161\u0161\u00ED \u010Detnost\u00ED lok\u00E1ln\u00EDch recidiv. V\u00FDskyt lok\u00E1ln\u00ED recidivy lze sn\u00ED\u017Eit radioterapi\u00ED. P\u0159edopera\u010Dn\u00ED chemoradioterapie prok\u00E1zala lep\u0161\u00ED l\u00E9\u010Debn\u00E9 v\u00FDsledky a ni\u017E\u0161\u00ED toxicitu ne\u017E l\u00E9\u010Dba poopera\u010Dn\u00ED. Jako potenciace se pou\u017E\u00EDv\u00E1 5-fluorouracil nebo kapecitabin. Receptor pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR) hraje d\u016Fle\u017Eitou \u00FAlohu pro zachov\u00E1n\u00ED norm\u00E1ln\u00ED funkce p\u0159i reparaci zdrav\u00FDch epiderm\u00E1ln\u00EDch tk\u00E1n\u00ED. Klinick\u00E9 studie s neoadjuvantn\u00ED chemoradioterapi\u00ED prok\u00E1zaly u pacient\u016F s adenokarcinomy se zv\u00FD\u0161enou expres\u00ED EGFR ni\u017E\u0161\u00ED v\u00FDskyt patologick\u00E9 kompletn\u00ED remise a krat\u0161\u00ED p\u0159e\u017Eit\u00ED pacient\u016F. S rozvojem molekul\u00E1rn\u00ED biologie prob\u011Bhlo n\u011Bkolik klinick\u00FDch studi\u00ED, kter\u00E9 hodnotily kombinaci neoadjuvantn\u00ED chemoradioterapie a anti-EGFR c\u00EDlen\u00E9 l\u00E9\u010Dby, s c\u00EDlem zlep\u0161it l\u00E9\u010Debn\u00E9 v\u00FDsledky. Zat\u00EDm tento postup nepat\u0159\u00ED k l\u00E9\u010Debn\u00FDm standard\u016Fm." . . "Neoadjuvantn\u00ED chemoradioterapie karcinomu rekta v kombinaci s inhibitory receptoru pro r\u016Fstov\u00FD epiderm\u00E1ln\u00ED faktor" . "0862-495X" . "3" . "I" . "1"^^ . "Barto\u0161, J." . "Neoadjuvantn\u00ED chemoradioterapie karcinomu rekta v kombinaci s inhibitory receptoru pro r\u016Fstov\u00FD epiderm\u00E1ln\u00ED faktor" . "[2C5C5C216A7A]" . "Karcinom rekta se li\u0161\u00ED od karcinomu tlust\u00E9ho st\u0159eva vy\u0161\u0161\u00ED \u010Detnost\u00ED lok\u00E1ln\u00EDch recidiv. V\u00FDskyt lok\u00E1ln\u00ED recidivy lze sn\u00ED\u017Eit radioterapi\u00ED. P\u0159edopera\u010Dn\u00ED chemoradioterapie prok\u00E1zala lep\u0161\u00ED l\u00E9\u010Debn\u00E9 v\u00FDsledky a ni\u017E\u0161\u00ED toxicitu ne\u017E l\u00E9\u010Dba poopera\u010Dn\u00ED. Jako potenciace se pou\u017E\u00EDv\u00E1 5-fluorouracil nebo kapecitabin. Receptor pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR) hraje d\u016Fle\u017Eitou \u00FAlohu pro zachov\u00E1n\u00ED norm\u00E1ln\u00ED funkce p\u0159i reparaci zdrav\u00FDch epiderm\u00E1ln\u00EDch tk\u00E1n\u00ED. Klinick\u00E9 studie s neoadjuvantn\u00ED chemoradioterapi\u00ED prok\u00E1zaly u pacient\u016F s adenokarcinomy se zv\u00FD\u0161enou expres\u00ED EGFR ni\u017E\u0161\u00ED v\u00FDskyt patologick\u00E9 kompletn\u00ED remise a krat\u0161\u00ED p\u0159e\u017Eit\u00ED pacient\u016F. S rozvojem molekul\u00E1rn\u00ED biologie prob\u011Bhlo n\u011Bkolik klinick\u00FDch studi\u00ED, kter\u00E9 hodnotily kombinaci neoadjuvantn\u00ED chemoradioterapie a anti-EGFR c\u00EDlen\u00E9 l\u00E9\u010Dby, s c\u00EDlem zlep\u0161it l\u00E9\u010Debn\u00E9 v\u00FDsledky. Zat\u00EDm tento postup nepat\u0159\u00ED k l\u00E9\u010Debn\u00FDm standard\u016Fm."@cs . "Neoadjuvantn\u00ED chemoradioterapie karcinomu rekta v kombinaci s inhibitory receptoru pro r\u016Fstov\u00FD epiderm\u00E1ln\u00ED faktor"@cs . "32112" . . "3"^^ . "Neoadjuvantn\u00ED chemoradioterapie karcinomu rekta v kombinaci s inhibitory receptoru pro r\u016Fstov\u00FD epiderm\u00E1ln\u00ED faktor"@cs . "Rectal adenocarcinoma, in contrast to colorectal carcinoma, is typical of its high local reccurence rate. Radiotherapy is proved to reduce the incidence of recurrences. Neoadjuvant chemoradiotherapy demonstrated better treatment results than adjuvant chemoradiotherapy. Standard cytotoxic agents involved in combination therapy are 5-flurouracil or capecitabin. Epidermal growth factor receptor (EGFR) is supposed to play an important role in cell-cycle regulation, proliferation, differentiation, and surviving of normal epithelial tissues. EGFR overexpression in patients with rectal adenocarcinoma is associated with radioresistance of malignant tissues, lower rates of patological complete response after neoadjuvant chemoradiation and generally poor survival. There are many clinical studies describing combination of neoadjuvant chemoradiotherapy with EGFR inhibitors, however, this regimen has not gained an acceptance as a standard of treatmentment."@en . "27" . . . . "Richter, I." . . "Combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma"@en . . . "RIV/00216208:11110/14:10283162!RIV15-MSM-11110___" . . "Klinick\u00E1 onkologie" . .